Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Biotechnology

Healthcare
$162.86 -0.45%

-$0.71 today

Market cap
$16.48B
Beta
0.40
P/E (TTM)
23.8
EPS (TTM)
$6.65
52W Low $122.14High $169.57

Volume 1.60M

Average 1.18M

NBIX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Neurocrine Biosciences, Inc.NASDAQ: NBIX

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q3 FY2026 stock-based compensation of $54.3M rose 1.1% year over year, behind the +4.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 16.5% from the prior quarter. Over 3 fiscal years it compounded at +8.0% a year.

Context

  • Stock-based compensation amounted to 7.6% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.1% toward the trailing-twelve-month pace of +4.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$54.3M-16.5% QoQ
Last fiscal yearDec 2025
$217.9M+11.5% YoY
LTMSep 2026
$235.1M+4.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.1%——
1 year+11.5%——
3-year CAGR+8.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
217.9M USD
Year-over-year change
+11.5%
4-year CAGR
+12.9%

Stock-Based Compensation vs competitors

How NBIX compares with its peers on the latest reported figures

  • NBIX's LTM Sep 2026 stock-based compensation of $235.1M is the 2nd largest of the 10 companies compared; the peer median is $58M.
  • Its year-over-year change of +4.2% is the 5th highest of 10, against a peer median of -4.5%.
  • Stock-based compensation amounts to 6.4% of revenue for NBIX, versus a peer median of 8.0%.
NBIX Competitors Peer median
Stock-Based Compensation for NBIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$424.81M +46.2%+9.5%9.0%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$235.1M +4.2%+8.0%6.4%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$96.42M +5.3%+35.5%12.4%
BHVNBiohaven Ltd.LTM Jun 2026$85.94M -13.0%-16.6%—
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$59.52M -4.5%—5.2%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$58M +87.8%+23.4%7.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$27.96M -33.3%+53.3%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$21.78M +70.4%+213.9%108.9%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$9.07M -23.3%-16.5%4.2%
GHRSGH Research PLCLTM Mar 2026$1.88M -32.3%——
Peer median (excluding NBIX) $58M-4.5%+23.4%8.0%

Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income89.6M154.5M249.7M341.3M478.6M
Depreciation & Amortization10.9M15.6M21.3M27.1M30.1M
Deferred Income Tax4.3M19.1M(56.7M)(123.1M)165.4M
Stock-Based Compensation134.2M173.1M194.3M195.5M217.9M
Change in Working Capital16.7M(67.4M)28.2M(19.2M)(128.8M)
Accounts Receivables(28.4M)(162.2M)(89.3M)(39.8M)(210.5M)
Inventory(2.5M)(2.6M)5.4M(19.1M)(15.3M)
Accounts Payables00000
Other Working Capital47.6M97.4M112.1M39.7M97M
Other Non-Cash Items800K44.5M(46.9M)173.8M19.5M
Operating Cash Flow256.5M339.4M389.9M595.4M782.7M
Capital Expenditures(23.4M)(16.5M)(28.3M)(38.2M)(34M)
Acquisitions (Net)0(42.7M)000
Purchases of Investments(804.7M)(628.9M)(1.41B)(1.06B)(1.32B)
Sales of Investments697.9M511M972.4M967.5M1.09B
Other Investing Activities00000
Investing Cash Flow(130.2M)(177.1M)(467.1M)(126.8M)(264.4M)
Debt Repayment(100K)(279M)0(308.8M)0
Common Stock Issued27.5M44.7M65.3M122.1M129.4M
Common Stock Repurchased000(300M)(167.7M)
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow27.4M(234.3M)65.3M(486.7M)(38.3M)
Effect of Forex Changes0(1.3M)300K00
Net Change in Cash153.7M(73.3M)(11.6M)(18.1M)480M
Free Cash Flow233.1M322.9M361.6M557.2M748.7M

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Intrinsic Alpha fair value

Locked

Current Price

$162.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.